| Not Yet Recruiting | Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma NCT07316010 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Not Yet Recruiting | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell NCT07164469 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleu NCT07052305 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558 | Lyell Immunopharma, Inc. | Phase 3 |
| Recruiting | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma NCT06919939 | University of Miami | Phase 2 |
| Recruiting | Glofitamab in Real Life NCT06994169 | The Lymphoma Academic Research Organisation | — |
| Recruiting | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL NCT07215585 | AstraZeneca | Phase 3 |
| Recruiting | The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Rela NCT07240194 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients W NCT07126236 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Recruiting | A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T NCT06167785 | University Health Network, Toronto | Phase 2 |
| Not Yet Recruiting | Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Lar NCT06988085 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies NCT06743503 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym NCT06760156 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | BHB & CAR-T for Lymphomas NCT06610344 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Not Yet Recruiting | CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk NCT06567366 | Ruijin Hospital | Phase 2 |
| Not Yet Recruiting | JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases NCT06567080 | RenJi Hospital | Phase 1 |
| Recruiting | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B NCT06071871 | University College, London | Phase 2 |
| Recruiting | CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma NCT06479356 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma NCT06486051 | Malaghan Institute of Medical Research | Phase 2 |
| Active Not Recruiting | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participant NCT06356129 | Celgene | Phase 3 |
| Recruiting | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL NCT06500273 | Allogene Therapeutics | Phase 2 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) NCT06285422 | Sana Biotechnology | Phase 1 |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Recruiting | A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL NCT06375733 | Genfleet Therapeutics (Shanghai) Inc. | Phase 1 / Phase 2 |
| Recruiting | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen R NCT05887167 | Joshua Sasine, MD, PhD | Phase 1 |
| Recruiting | Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clin NCT07236203 | Fudan University | — |
| Recruiting | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies NCT06045910 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracy NCT06045247 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Relmacabtagene Autoleucel in Hematologic Malignancies NCT06142188 | Shanghai Ming Ju Biotechnology Co., Ltd. | — |
| Recruiting | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL NCT06104592 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Withdrawn | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before NCT05929716 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, a NCT06047080 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers NCT05940272 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma NCT05820841 | Universität des Saarlandes | Phase 3 |
| Recruiting | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms NCT06593145 | FamiCordTx | Phase 1 |
| Recruiting | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory NCT05794958 | Stanford University | Phase 1 |
| Recruiting | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma NCT05826535 | Lyell Immunopharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062 | Synthekine | Phase 1 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies NCT05643742 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma NCT05757700 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Agg NCT05464329 | Washington University School of Medicine | Phase 1 |
| Recruiting | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy NCT05377307 | Pell Bio-Med Technology Co., Ltd. | — |
| Unknown | Relmacabtagene Autoleucel in Patients With LBCL NCT06142175 | Shanghai Ming Ju Biotechnology Co., Ltd. | — |
| Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Re NCT05429268 | Incyte Corporation | Phase 3 |
| Recruiting | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-c NCT05464719 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell NCT05326243 | Pell Bio-Med Technology Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | PD-L1 PET-imaging During CAR T-cell Therapy NCT05404048 | University Medical Center Groningen | Phase 2 |
| Recruiting | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lym NCT05648019 | KK Women's and Children's Hospital | Phase 2 |
| Completed | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting NCT05108805 | Vanderbilt-Ingram Cancer Center | Phase 4 |
| Recruiting | CAR-T Followed by Bispecific Antibodies NCT04889716 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Unknown | Study of Efficacy of BZ019 in Large B-cell Lymphoma NCT05472610 | Shanghai Mengchao Cancer Hospital | Phase 2 |
| Completed | CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma NCT04690192 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Withdrawn | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity NCT04503538 | Wake Forest University Health Sciences | N/A |
| Completed | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) NCT04566978 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Completed | Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT NCT07236151 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma NCT04250324 | Shanghai Cell Therapy Group Co.,Ltd | Phase 1 |
| Active Not Recruiting | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL NCT03960840 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | MT2017-45: CAR-T Cell Therapy for Heme Malignancies NCT03642626 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Unknown | Risk Adapted Therapy in Diffuse Large B Cell Lymphoma NCT03188198 | Mansoura University | Phase 2 |
| Completed | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma NCT00118209 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Approved For Marketing | Expanded Access Program for Epcoritamab NCT05733650 | Genmab | — |
| Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Cilole NCT05776160 | Kite, A Gilead Company | — |